Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in Active Ankylosing Spondylitis
2004-003299-12Phase 3Completed
- Sponsor
- Janssen Biologics B.V.
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Golimumab with Placebo (2 arms). Primary endpoint: ASAS20 response at Week 14. Started Dec 2005; status: completed.
02
Drugs
golimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2004-003299-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003299-12.